Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) ranks among the best AI stocks to buy according to analysts. On December 17, JPMorgan raised Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) from a Neutral ...

Mutual fund outlook 2026: Lessons from a volatile 2025 and where investors go next (Image: AI generated/FE) For mutual fund investors, 2025 turned out to be a year that tested their patience. After a ...

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

Farran Powell is the managing editor of investing at Forbes Advisor. She was previously the assistant managing editor of investing at U.S. News & World Report. Her work has appeared in numerous ...

The three main differences between index funds and mutual funds are management style, investment objective and cost. Index funds tend to be the clear winner over the long term. Many, or all, of the ...

Fed rate cuts could boost mid-cap companies—and the earnings outlook is strong. The T. Rowe Price Diversified Mid Cap Growth fund stands to gain. Paul Wick of Seligman Investments has piloted his ...

MassMutual’s flexible payment options are best for those interested in paying off policies early. New York Life is known for fast applications while Penn Mutual has lots of rider options to customize ...

The end of the year is when investors take stock of their portfolios. They evaluate how their investments fared and decide on changes. To that end, I thought I’d review how the 10 largest actively ...

Top 5 small-cap mutual funds delivering 30%+ returns in 2025 include Quant, Nippon, Tata, Bandhan, and Invesco schemes. Small-cap funds can go up fast and fall just as quickly. The last year has been ...

James Chen, CMT is an expert trader, investment adviser, and global market strategist. Thomas J. Brock is a CFA and CPA with more than 20 years of experience in various areas including investing, ...